Wanjia Group Holdings 401.HK · HKD

Its shares trade on HKEX under the ticker 401.HK. It has been listed since 11 October 2013. In the fiscal year to 31 March 2025, it reported revenue of HK$161.7m and a net loss of HK$6.6m. At that date it held total assets of HK$106.8m and shareholders' equity of HK$66.9m.

Wanjia Group Holdings Ltd. wholesales and distributes pharmaceutical and healthcare products. The company employs 125 full-time employees The company went IPO on 2013-10-11. The company operates through two businesses, including Pharmaceutical Wholesales and Distribution businesses and Pharmaceutical Retail Chain businesses. The firm mainly distributes pharmaceutical products to customers in the Fujian Province and retails pharmaceutical products in Guangdong, Hunan, Hubei, Jiangxi, Anhui and Zhejiang, among others. The pharmaceutical products provided by its retail stores include prescription medicines, over-the-counter medicines, healthcare food products, traditional Chinese medicines, medical supplies and medical devices.

Figures and description from our data supplier, not checked against the company's own report.

• Jia Jun WangChief Executive Officer & Executive Director, since 2018
• Sze Kin TamSecretary, since 2019
• Jia Jun WangChief Executive Officer & Executive Director, since 2018
• Zhi Xin Xiao, MDNon-Executive Director, since 2022
• Man Ho, CFA, EMBAIndependent Non-Executive Director, since 2018
• Yong Ping Liu, PhDIndependent Non-Executive Director, since 2014
• Hon Kit Wong, CPAIndependent Non-Executive Director, since 2013

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.